Perrigo Management

Management criteria checks 2/4

Perrigo's CEO is Patrick Lockwood-Taylor, appointed in Jun 2023, has a tenure of 1.42 years. total yearly compensation is $6.67M, comprised of 9.1% salary and 90.9% bonuses, including company stock and options. directly owns 0.033% of the company’s shares, worth €1.16M. The average tenure of the management team and the board of directors is 2.5 years and 5.9 years respectively.

Key information

Patrick Lockwood-Taylor

Chief executive officer

US$6.7m

Total compensation

CEO salary percentage	9.1%
CEO tenure	1.4yrs
CEO ownership	0.03%
Management average tenure	2.5yrs
Board average tenure	5.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Patrick Lockwood-Taylor's remuneration changed compared to Perrigo's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 28 2024	n/a	n/a	-US$147m
Jun 29 2024	n/a	n/a	-US$114m
Mar 30 2024	n/a	n/a	US$800k
Dec 31 2023	US$7m	US$605k	-US$4m

Compensation vs Market: Patrick's total compensation ($USD6.67M) is above average for companies of similar size in the German market ($USD1.95M).

Compensation vs Earnings: Insufficient data to compare Patrick's compensation with company performance.

CEO

Patrick Lockwood-Taylor

1.4yrs

Tenure

US$6,672,584

Compensation

Mr. Patrick Lockwood-Taylor has been President, Chief Executive Officer and Director at Perrigo Company plc since June 30, 2023. He had been Regional President and Head North American Consumer Health Busin...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Patrick Lockwood-Taylor	President	1.4yrs	US$6.67m	0.033% € 1.2m
Eduardo Bezerra	Executive VP & CFO	2.5yrs	US$3.05m	0.011% € 395.4k
Ronald Janish	Chief Transformation Officer and Executive VP of Global Operations & Supply Chain	9.1yrs	US$2.23m	0.019% € 654.0k
Svend Andersen	Advisor	7.8yrs	US$2.55m	0.059% € 2.1m
Kyle Hanson	Advisor	less than a year	US$2.28m	0.0082% € 284.8k
Shannon Hukill	Senior Director of Technical Operations	13.2yrs	no data	no data
Alison Ives	Executive VP & Chief Scientific Officer	2.4yrs	no data	0.014% € 471.8k
Bradley Joseph	Vice President of Global Investor Relations & Corporate Communications	no data	no data	no data
Charles Atkinson	Executive VP	less than a year	no data	no data
Mary Reilly-Brest	Director of Global Organizational and Human Resource Development	16.8yrs	no data	no data
Robert Willis	Chief Human Resources Officer & Executive VP	5.7yrs	no data	0.023% € 805.1k
Catherine C. Schmelter	Executive VP and President of Consumer Self-Care Americas & Global Portfolio Optimization	1.2yrs	no data	0.0019% € 66.0k

2.5yrs

Average Tenure

55yo

Average Age

Experienced Management: PIG's management team is considered experienced (2.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Patrick Lockwood-Taylor	President	1.4yrs	US$6.67m	0.033% € 1.2m
Jeffrey Kindler	Independent Director	7.8yrs	US$399.99k	0.017% € 588.4k
Donal O'Connor	Independent Director	10yrs	US$405.30k	0.020% € 682.6k
Bradley Alford	Independent Director	7.8yrs	US$387.49k	0.026% € 921.0k
Albert Manzone	Independent Director	2.3yrs	US$387.49k	0.0054% € 189.5k
Orlando Ashford	Independent Chairman of the Board	3.9yrs	US$532.99k	0.012% € 402.4k
Julia Brown	Director	less than a year	US$12.53k	no data
Geoffrey Parker	Independent Director	8yrs	US$387.49k	0.038% € 1.3m
Adriana Karaboutis	Independent Director	7.5yrs	US$390.99k	0.016% € 575.1k
Katherine Doyle	Independent Director	4.3yrs	US$392.80k	0.0044% € 153.6k

5.9yrs

Average Tenure

60yo

Average Age

Experienced Board: PIG's board of directors are considered experienced (5.9 years average tenure).

Perrigo Management

Management criteria checks 2/4

Key information

Recent management updates

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Advisor recently sold €872k worth of stock

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

Perrigo Company plc, Annual General Meeting, May 02, 2024

Recent updates

Third quarter dividend of US$0.28 announced

New major risk - Dividend sustainability

Third quarter 2024 earnings released: US$0.13 loss per share (vs US$0.11 profit in 3Q 2023)

Perrigo Company plc Provides Revenue Guidance for the Fiscal Year 2024

Perrigo Company plc Announces Quarterly Dividend, Payable on December 17, 2024

Perrigo Company plc to Report Q3, 2024 Results on Nov 06, 2024

Perrigo Company plc Appoints Charles Atkinson, as Executive Vice President, General Counsel and Secretary

Upcoming dividend of US$0.28 per share

Advisor recently sold €872k worth of stock

Perrigo Company plc Appoints David Ball as Executive Vice President and Chief Brand and Digital Officer

Second quarter dividend of US$0.28 announced

Second quarter 2024 earnings released: US$0.77 loss per share (vs US$0.066 profit in 2Q 2023)

Perrigo Company plc Reports Impairment Charges for the Second Quarter Ended June 29, 2024

Perrigo Company plc to Report Q2, 2024 Results on Aug 02, 2024

Esteve Healthcare S.L. completed the acquisition of HRA Pharma Rare Diseases America, LLC from Perrigo Company plc.

Perrigo Company plc Appoints Todd Penegor as Member of Board and to Serve on Audit Committee, Effective June 21, 2024

Perrigo Company plc Announces Executive Changes

Upcoming dividend of US$0.28 per share

Perrigo Company plc Reaffirms Earnings Guidance for 2024

First quarter 2024 earnings released: EPS: US$0.03 (vs US$0.008 loss in 1Q 2023)

Fourth quarter dividend of US$0.28 announced

Perrigo Company plc Announces Quarterly Dividend, Payable on June 18, 2024

Esteve Healthcare S.L. agreed to acquire HRA Pharma Rare Diseases America, LLC from Perrigo Company plc (NYSE:PRGO) for approximately €280 million.

Perrigo Company plc to Report Q1, 2024 Results on May 07, 2024

Perrigo Company plc, Annual General Meeting, May 02, 2024

Perrigo Company plc Announces Erica L. Mann Not to Stand for Re-Election to its Board of Directors

Fourth quarter dividend of US$0.28 announced

Perrigo Company plc Reports Impairment Charges for the Fourth Quarter Ended December 31, 2023

Perrigo Company plc Reports Earnings Guidance for the Fiscal Year 2024

Full year 2023 earnings released: US$0.033 loss per share (vs US$0.97 loss in FY 2022)

Perrigo Company plc Increases its Quarterly Dividend, Payable on March 26, 2024

Perrigo Company plc to Report Q4, 2023 Results on Feb 27, 2024

President recently bought €294k worth of stock

Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023

Perrigo Company plc Updates Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q3, 2023 Results on Nov 07, 2023

Perrigo Company plc Announces Executive Changes

Perrigo Company plc Reaffirms Earnings Guidance for the Fiscal 2023

Perrigo Company plc to Report Q2, 2023 Results on Aug 08, 2023

Perrigo Company plc Announces U.S. FDA Approval for Opill OTC Daily Oral Contraceptive

Perrigo Company plc Appoints Patrick Lockwood-Taylor as Its New Chief Executive Officer

Perrigo Announces U.S. FDA Approval for Nicotine Coated Mint Lozenge

Perrigo Company plc Announces FDA Approval of Opill®? for Over-The-Counter Use

Perrigo Company plc Reaffirms Sales Guidance for the Fiscal Year 2023

Perrigo Announces Quarterly Dividend, Payable on June 20, 2023

Perrigo Company plc to Report Q4, 2022 Results on Feb 27, 2023

Theodore R. Samuels Not to Stand for Re-Election to the Perrigo Company plc's Board of Directors

Perrigo Company plc Provides Earnings Guidance for the Fiscal Year 2022

Perrigo Company plc Announces Quarterly Dividend, Payable on December 20, 2022

Perrigo Company plc (NYSE:PRGO) acquired Good Start Packaging, Inc. from Nestle Canada Inc.

Perrigo Company plc to Report Q3, 2022 Results on Nov 08, 2022

Perrigo Company plc Announces Litigation Update

Perrigo Company Revised Earnings Guidance for the Full Year of 2022

Perrigo Company plc Declares Quarterly Dividend, Payable on September 20, 2022

Perrigo Company plc to Report Q2, 2022 Results on Aug 09, 2022

Perrigo Company plc Appoints Albert A. Manzone to Serve as A Member of the Board of Directors and Member of the Talent & Compensation Committee, to Be Effective July 30, 2022

Perrigo Company plc Promotes Alison Ives to Executive Vice President and Chief Scientific Officer

Perrigo Company plc Announces U.S. FDA Approval for Omeprazole Magnesium Delayed-Release Mini Capsules

Perrigo Company plc Announces Retirement of Todd Kingma as Executive Vice President, General Counsel, and Corporate Secretary, Effective August 31, 2022

Perrigo Company plc Raises Earnings Guidance for the Fiscal Year 2022

Perrigo Company plc Declares Quarterly Dividend, Payable on June 21, 2022

Perrigo Company plc Provides Earnings Guidance for the Year 2022

Perrigo Company plc Announces Quarterly Dividend, Payable on March 17, 2022

Perrigo Company plc to Report Q4, 2021 Results on Mar 01, 2022

Perrigo Company plc(TASE:PRGO) dropped from TA-35 Index

Perrigo Announces Voluntary Delisting from the Tel Aviv Stock Exchange

Third quarter 2021 earnings released: US$0.40 loss per share (vs US$1.13 loss in 3Q 2020)

Perrigo Company plc (NYSE:PRGO) signed a binding offer to acquire HRA Pharma, SA from funds affiliated with Astorg Partners and Goldman Sachs Asset Management, L.P. for transaction value of €1.8 billion.

Upcoming dividend of US$0.24 per share